Lapatinib is a Medicine belongs to Antineoplastic group whose information about Brand can be referenced from   Book : Martindale    Page : 811   Edition : 37  

  ►   Brandname : Tykerb
  ►  Strength : Tablet with

Reference of this Medicine for its Strength can be taken from   Book : Martindale    Page : 811   Edition : 37  
A Route of administration in pharmacology and toxicology is the path by which a drug, fluid, poison, or other substance is taken into the body. Routes of administration are generally classified by the location at which the substance is applied. Common examples include oral and intravenous administration.

  ►  Route of administration : Oral
Reference :-   Book : Martindale    Page : 810   Edition : 37  

Dosing of Medicine differ in Adult & Pediatrics ↓

Adult Dose

S.No Ailment   Route   Dose Min   Dose Max   Unit   Dosage Form   Frequency   Additional Info
1 Breast cancer Oral 1.25 gm o.d. Dose: Given with capecitabine: daily 1 to21 of a 21-day cycle. Capecitabine is given at a dose of 2 g/m2 daily (given orally in 2 doses about 12 hours apart, with food or within 30 minutes after food) on days 1 to 14 of the cycle. Treatment may be continued until disease progression or unacceptable toxicity occurs. If a daily dose is missed, the next day’s dose should not be doubled.
2 Breast cancer Oral 1.5 gm o.d. Dose: Given with aromatase inhibitor.
3 Breast cancer Oral 500 mg Dose given daily when given with a potent CYP3A4 inhibitor; if the inhibitor is stopped, a washout period of about 1 week should be allowed before the lapatinib dose is increased to the usual recommended dose.

Ref :-  Book : Martindale    Page : 811   Edition : 37  

Pediatric Dose

S.No Ailment   Age Min   Age Max   Weight ( Kg ) Route   Dose Min   Dose Max   Unit   Dosage Form   Frequency  Additional Info  

Ref :- Book :    Page :    Edition :   
►  Side Effect : Gastrointestinal disturbances, Dermatological reactions, Palmar-plantar erythrodysesthesia, Rashes, Fatigue, Diarrhoea, Decreases in left ventricular ejection fraction (LVEF), Prolongation of the QT interval, Stomatitis, Mucosal irritation, Pain in extremities, Back pain, Dyspnoea, Insomnia, Epistaxis, Alopecia, Nail disorders, Paronychia, Hypersensitivity reactions, Anaphylaxis
Ref :-   Book : Martindale    Page : 810   Edition : 37.  

►  Drug Interaction : Drug interaction of Lapatinib is with ,  Carbamazapine , Ketoconazole
Ref :-   Book : Martindale    Page : 811   Edition : 37.  

  ►    Mechanism of Drug Drug Interaction :  Lapatinib tosilate undergoes extensive metabolism by cytochrome P450 isoenzyme CYP3A4. Inhibitors of CYP3A4, such as ketoconazole, can increase exposure to lapatinib. Conversely, CYP3A4 inducers, such as carbamazepine, can reduce exposure to lapatinib. Use of lapatinib with strong inhibitors or inducers of CYP3A4 should be avoided; if they are to be given together, dose adjustments may be required. Grapefruit juice may also increase plasma concentrations of lapatinib and should be avoided. In vitro studies indicate that lapatinib itself inhibits CYP3A4 and CYP2C8; it should be used cautiously with substrates of these isoenzymes that have a narrow therapeutic index. Lapatinib is a substrate of P-glycoprotein and P-glycoprotein inhibitors can increase plasma concentrations of lapatinib. Lapatinib itself also inhibits human Pglycoprotein and may in turn increase plasma concentrations of drugs that are substrates of P-glycoprotein.
Ref :-   Book : Martindale    Page : 811   Edition : 37.  

►  Contraindication : Hypomagnesaemia, Congenital QT prolongation, Antiarrhythmics, Cumulative high-dose anthracycline therapy, Interstitial lung disease, Pneumonitis, Severe pulmonary symptoms develop, Hepatotoxicity, Pre-existing severe hepatic impairment, Hypokalaemia
Ref :-   Book : Martindale    Page : 810   Edition : 37.  
  ►  Mechanism of Action :   Lapatinib tosilate is a dual tyrosine kinase inhibitor directed against two members of the human epidermal growth factor receptor family, namely epidermal growth factor receptor (EGFR; ErbB1) and human epidermal receptor type 2 (HER2; ErbB2).
Ref :-   Book : Martindale    Page : 811   Edition : 37.  

Pathway of DIETARY Product

​   ► Act.Comp / Nutrient / Food / Herb as follows :- NA

DIETARY Substance Interactions

​   ► This Medicine interact with :- NA

ContraIndication DIETARY Substance

​   ► This Medicine contraindicate with :- NA

►   Route of Elimination :   Faecal
Ref :-   Book : Martindale    Page : 811   Edition : 37.  

►    Plasma Half-life :   Min value :-   NA    Max value :-   NA

►    Peak Plasma Concentration :   Min value :-   4 hours,    Max value :-   NA
Ref :-   Book : Martindale    Page : 810   Edition : 37.